Digoxin is one of the oldest medications in clinical use — derived from the foxglove plant (Digitalis purpurea) and described pharmacologically by William Withering in 1785 — yet it remains on active nursing unit formularies today. Its narrow therapeutic index, complex electrolyte interactions, and distinctive toxicity syndrome make it a perennial focus of nursing board exams and a genuine source of patient harm when monitoring lapses.
For nursing students, digoxin is high-yield for multiple reasons: the mechanism explains both its therapeutic effect and why it becomes toxic; the toxicity signs follow a recognizable pattern across three body systems; the electrolyte interactions follow a logical biochemical logic; and the nursing responsibilities — pulse check, electrolyte monitoring, patient education — are concrete and testable. This guide covers all of it, from molecular mechanism to patient teaching, with 20 high-yield NCLEX tips and 20 NCLEX-style practice scenarios.
Use this article alongside the heart failure nursing guide for indication context, the cardiac arrhythmias overview for rhythm recognition, and the hypokalemia nursing guide and hyperkalemia nursing guide for the electrolyte interactions that drive toxicity risk.
Quick reference
| Parameter | Key facts |
|---|---|
| Drug class | Cardiac glycoside |
| Mechanism | Inhibits Na⁺/K⁺-ATPase → ↑ intracellular Ca²⁺ (positive inotropy); ↑ vagal tone → slows AV conduction (negative chronotropy) |
| Primary indications | Heart failure with reduced ejection fraction (HFrEF); atrial fibrillation rate control |
| Therapeutic range (HF) | 0.5–0.9 ng/mL (lower end preferred per DIG trial data) |
| Therapeutic range (AF) | 0.8–2.0 ng/mL cited historically; many sources now align with HF range |
| Half-life | ~36–48 hours (normal renal function) |
| Excretion | Primarily renal (60–80% unchanged) |
| Level draw timing | 6–8 hours post-dose (avoids distribution phase artifact) |
| Hold parameter | Apical pulse <60 bpm (adults); document and notify provider |
| Antidote | Digoxin immune Fab (Digibind, DigiFab) — for severe toxicity |
| Key toxicity potentiator | Hypokalemia (competes at Na⁺/K⁺-ATPase binding site) |
Mechanism of action
Understanding digoxin’s mechanism is not just a pharmacology exercise — it explains everything: why it strengthens cardiac contraction, why it slows heart rate, why hypokalemia makes it dangerous, and why overdose produces its characteristic toxicity pattern.
Step 1: Na⁺/K⁺-ATPase inhibition
Every cardiac myocyte has Na⁺/K⁺-ATPase pumps embedded in the cell membrane. These pumps run continuously, using ATP to push three sodium ions out of the cell while pulling two potassium ions in. This exchange maintains the electrochemical gradients that cells depend on — and specifically, it keeps intracellular sodium concentration low.
Digoxin binds directly to the extracellular surface of the Na⁺/K⁺-ATPase pump and inhibits it. With the pump partially blocked, sodium accumulates inside the myocyte. The elevated intracellular sodium then affects a second transport system: the Na⁺/Ca²⁺ exchanger (NCX), which normally exports calcium by coupling it to sodium influx. When intracellular sodium is already high, the NCX can no longer drive calcium out as effectively. Intracellular calcium concentration rises.
Step 2: Positive inotropy
The rise in intracellular calcium has a direct therapeutic effect. Calcium drives myocardial contraction — when sarcoplasmic reticulum calcium stores are larger, each action potential triggers a stronger contractile force. In a failing heart with reduced ejection fraction, this means more stroke volume per beat, improved cardiac output, and reduced symptoms of congestion. This is positive inotropy: increased contractile force without a rate increase.
Step 3: Negative chronotropy (vagal mechanism)
Digoxin’s rate-slowing effect operates through a different pathway. It sensitizes the cardiac baroreceptors and directly stimulates the vagus nerve (parasympathetic), increasing vagal tone to the sinoatrial (SA) and atrioventricular (AV) nodes. Enhanced vagal tone:
- Slows SA node firing rate (negative chronotropy)
- Slows conduction through the AV node (negative dromotropy), increasing the PR interval
This AV nodal slowing is the pharmacological basis for using digoxin in atrial fibrillation. The atria in AF fire chaotically at 400–600 impulses per minute — digoxin doesn’t stop this, but by slowing AV nodal conduction, it reduces how many of those impulses reach the ventricles, controlling ventricular rate.
Why the mechanism explains toxicity
Both positive inotropy and AV slowing depend on the same Na⁺/K⁺-ATPase inhibition. At therapeutic levels, the effect is calibrated and beneficial. At toxic levels, the inhibition becomes excessive:
- Too much calcium accumulation → spontaneous depolarizations, triggered arrhythmias (PVCs, ventricular tachycardia, bidirectional VT — the classic digoxin arrhythmia)
- Too much AV nodal suppression → high-degree AV block, junctional rhythms, complete heart block
- Excessive vagal stimulation → bradycardia, SA block
Crucially: hypokalemia worsens all of this. Potassium competes with digoxin for the same binding site on Na⁺/K⁺-ATPase. When serum potassium is low, digoxin binds more avidly to the pump — you get more Na⁺/K⁺-ATPase inhibition for the same serum digoxin level. A patient can have a “therapeutic” digoxin level and still be toxic if potassium is low. This is one of the most important clinical concepts in digoxin pharmacology.
Indications
Heart failure with reduced ejection fraction (HFrEF)
Digoxin is used as an adjunct therapy in patients with HFrEF (ejection fraction ≤40%) who remain symptomatic despite optimal doses of ACE inhibitors or ARBs, beta-blockers, and diuretics. It improves symptoms and exercise tolerance and reduces heart failure hospitalizations.
Critical point for NCLEX: The landmark DIG trial (1997) established what digoxin does and does not do in heart failure:
- Reduces HF hospitalizations — yes, statistically significant
- Reduces mortality — no. Digoxin does NOT improve survival in HF
- In post-hoc subgroup analysis, lower serum digoxin levels (0.5–0.9 ng/mL) were associated with better outcomes than higher levels; levels above 1.0–1.2 ng/mL were associated with increased mortality
This is why the therapeutic target for HF has shifted downward. The old “therapeutic range” of 1.5–2.0 ng/mL that many older textbooks still cite reflects dosing before the DIG trial data changed practice.
Digoxin is not first-line for HF. It is added after the evidence-based foundation (ACE inhibitor/ARB/ARNI, beta-blocker, mineralocorticoid antagonist) is optimized. It has no role in HF with preserved ejection fraction (HFpEF).
Atrial fibrillation — rate control
Digoxin controls ventricular rate in AF through its vagal effect on AV nodal conduction. It is most effective at rest and in sedentary patients; it loses efficacy during exercise because sympathetic tone overrides the vagal effect. For this reason, beta-blockers or calcium channel blockers are generally preferred for rate control in active patients.
Digoxin is sometimes used as an add-on when beta-blockers and non-dihydropyridine CCBs (diltiazem, verapamil) are insufficient or not tolerated.
What digoxin does NOT do
- Does not terminate AF or restore sinus rhythm (not an antiarrhythmic for rhythm control)
- Does not reduce mortality in heart failure
- Is not first-line for any indication when better-tolerated alternatives exist
- Does not work well for rate control during exercise or stress (sympathetic override)
Pharmacokinetics
Understanding digoxin’s pharmacokinetics helps explain why dosing errors are dangerous and why monitoring is non-negotiable.
Absorption: Oral bioavailability is approximately 60–80% for standard tablets. The IV form has 100% bioavailability. Food does not significantly affect absorption, but high-fiber meals can reduce it slightly.
Distribution: Digoxin distributes extensively into tissues, including skeletal muscle and cardiac tissue. The volume of distribution is very large (~7 L/kg). This is relevant to toxicity: serum levels drawn too early after a dose reflect the distribution phase, not the tissue-equilibrated level. This is why levels must be drawn 6–8 hours post-dose.
Protein binding: Low (20–25%), meaning changes in albumin have less effect on free drug compared to highly protein-bound medications.
Metabolism: Minimal hepatic metabolism. Most digoxin is excreted unchanged by the kidneys.
Excretion: 60–80% renal excretion (unchanged). This has critical implications:
- Renal impairment dramatically prolongs the effective half-life and increases toxicity risk
- Any condition reducing GFR — AKI, CKD, dehydration, NSAIDs, contrast dye — increases digoxin accumulation
- Doses must be reduced and monitoring intensified in renal impairment
Half-life: Approximately 36–48 hours in patients with normal renal function. In severe renal impairment, the half-life can extend to 3.5–5 days. This means:
- It takes 5–7 half-lives to reach steady state after starting or changing dosing (7–14 days with normal renal function)
- After stopping digoxin for toxicity, the drug takes days to clear — not hours
Narrow therapeutic index: The difference between the therapeutic and toxic plasma concentration is small. The minimum effective concentration and the concentration producing toxicity are close together, leaving little room for error in dosing, monitoring, or patient adherence.
Loading vs. maintenance dosing
Loading dose (digitalization): A rapid loading strategy can be used when a quick effect is needed (e.g., acute AF with rapid ventricular response). Oral or IV loading doses are given in divided amounts over 24 hours. Loading is less commonly used than it once was.
Maintenance dosing: Most patients are started on a low maintenance dose (typically 0.125–0.25 mg/day orally) without loading, accepting the 7–14 days to steady state. This is safer. Maintenance dose is adjusted based on renal function, age, weight, and serum levels.
Elderly patients and renal impairment: Both reduce digoxin clearance. In elderly patients, lower starting doses (0.0625–0.125 mg/day) and careful monitoring are standard.
Therapeutic drug monitoring
Digoxin is one of a small group of medications requiring routine serum level monitoring because of its narrow therapeutic index and significant inter-patient variability in pharmacokinetics.
Current therapeutic ranges
| Indication | Target serum digoxin level | Notes |
|---|---|---|
| Heart failure (HFrEF) | 0.5–0.9 ng/mL | Lower end preferred; levels >1.2 ng/mL associated with worse outcomes in DIG trial subgroup analysis |
| Atrial fibrillation | 0.8–2.0 ng/mL (historical); many now target ≤1.0 ng/mL | Rate control effect does not require levels above 0.9 ng/mL in most patients; higher levels increase toxicity risk without benefit |
| Toxic range | >2.0 ng/mL | Toxicity can occur at lower levels with hypokalemia, hypomagnesemia, or hypercalcemia |
Important nuance: Serum level does not reliably predict toxicity. A patient with K⁺ of 2.8 mEq/L and a digoxin level of 1.0 ng/mL may show toxicity signs, while a patient with normal electrolytes and a digoxin level of 2.2 ng/mL may be tolerating the drug. Electrolyte status must always be interpreted alongside the serum level.
When to draw levels
Timing matters enormously. Drawing levels too soon after a dose produces falsely elevated readings because of the distribution phase. The drug takes 6–8 hours to equilibrate between serum and tissue compartments after an oral dose.
- Draw 6–8 hours after the last oral dose (or at least 6 hours after IV dose)
- Drawing a trough (just before the next scheduled dose) is acceptable if the dosing interval is 24 hours — this naturally satisfies the 6–8 hour rule
- Mark the sample with the time drawn and the time of last dose
Frequency of monitoring:
- After initiating therapy or changing dose: draw level after steady state is reached (7–14 days for normal renal function, longer in renal impairment)
- Stable patients on long-term therapy: every 6–12 months, or more frequently with renal function changes
- Any time toxicity is suspected: draw immediately regardless of when the last dose was given (you want to know the level, even if the timing is not optimal for standard therapeutic monitoring)
- After any significant change in renal function, significant illness, or new interacting medication
Digoxin toxicity
Digoxin toxicity is one of the most important clinical syndromes for nurses to recognize because it is serious, treatable, and easy to miss if you are not looking for the full pattern. Signs appear across three body systems: gastrointestinal, cardiac, and neurological/visual.
Who is at highest risk
- Patients with renal impairment (reduced clearance)
- Elderly patients (reduced renal function, lower lean body mass, altered pharmacokinetics)
- Patients with hypokalemia, hypomagnesemia, or hypercalcemia
- Patients on interacting medications (amiodarone, quinidine, verapamil, diltiazem — all raise digoxin levels)
- Acute accidental or intentional overdose
The three categories of toxicity signs
| Category | Signs and symptoms | Mechanism | Clinical notes |
|---|---|---|---|
| Gastrointestinal (often first) |
Anorexia (loss of appetite), nausea, vomiting, abdominal pain, diarrhea | Direct stimulation of chemoreceptor trigger zone (CTZ) in the medulla; GI tract also has Na⁺/K⁺-ATPase pumps | GI symptoms are frequently the earliest sign of toxicity — often appearing before cardiac changes. Any patient on digoxin who develops new nausea or anorexia should have electrolytes and a digoxin level checked |
| Cardiac | Bradycardia; prolonged PR interval; heart block (1st, 2nd, 3rd degree); junctional rhythms; PVCs (especially bigeminy); ventricular tachycardia; bidirectional VT; "regularized AF" (regular rhythm in known AF patient) | Excessive AV nodal suppression (vagal effect); excessive intracellular calcium causing triggered activity and spontaneous depolarizations | "Regularized AF" is a hallmark sign — the previously irregular rhythm of AF becomes regular, indicating complete AV block with a junctional escape rhythm taking over. This is a dangerous arrhythmia requiring immediate intervention |
| Neurological / visual | Yellow-green vision (xanthopsia); seeing halos or rings around lights; blurred vision; photophobia; confusion; disorientation; delirium; headache; fatigue; weakness | CNS Na⁺/K⁺-ATPase inhibition; accumulation in neural tissue; visual cortex effects | Yellow-green halos are the classic visual symptom and a well-known board question. The theory that Van Gogh's "Starry Night" (with its characteristic halos) was painted during digitalis treatment for epilepsy is frequently cited as a teaching point — though it remains debated. Neurological symptoms often precede cardiac arrhythmias in chronic toxicity |
Acute vs. chronic toxicity
Acute toxicity (accidental or intentional overdose in someone not previously taking digoxin):
- Hyperkalemia often develops (massive Na⁺/K⁺-ATPase inhibition blocks K⁺ uptake into cells)
- Serum digoxin levels are often very high
- GI and cardiac symptoms are prominent
Chronic toxicity (accumulation over time in patients on maintenance therapy):
- More common, and more insidious
- Hypokalemia and hypomagnesemia often play a contributing role
- Serum digoxin level may be within or just above the “therapeutic” range
- Neurological and GI symptoms often appear first
”Regularized AF” — the cardiac signature of digoxin toxicity
This bears emphasis because it is a classic exam and clinical scenario. A patient with known atrial fibrillation (which produces an irregularly irregular rhythm) develops a regular rhythm on the monitor. This “regularization” does not mean the AF has converted to sinus rhythm. It means complete AV block has developed, with a junctional escape rhythm (regular, at 40–60 bpm) taking over the ventricular response. The atria are still in chaotic fibrillation, but no impulses are getting through the AV node — it is completely blocked by digoxin. This is a medical emergency.
Electrolyte interactions
Electrolyte management is inseparable from safe digoxin administration. Nurses must understand not only which electrolytes matter but why — because the mechanisms dictate which direction each electrolyte shifts the toxicity risk.
| Electrolyte | Direction of change | Effect on digoxin toxicity risk | Mechanism | Nursing implication |
|---|---|---|---|---|
| Potassium (K⁺) | ↓ Hypokalemia | Markedly increases risk | K⁺ and digoxin compete for the same binding site on Na⁺/K⁺-ATPase. Low K⁺ means less competition — digoxin binds more avidly and produces more pump inhibition for the same serum level | Monitor K⁺ closely; maintain K⁺ 4.0–5.0 mEq/L in patients on digoxin; loop diuretics are a major culprit for hypokalemia in this population — see hypokalemia nursing guide |
| Potassium (K⁺) | ↑ Hyperkalemia | Protective (physiologically) | Elevated K⁺ competes with digoxin for the binding site — digoxin binds less, pump inhibition is reduced. However, hyperkalemia from acute toxicity itself is a sign of severe poisoning, not a therapeutic goal. Note: giving calcium (e.g., for hyperkalemia treatment) can worsen digoxin toxicity | Hyperkalemia in a known AF patient on digoxin — consider whether it represents acute toxicity. Review the hyperkalemia nursing guide for management context |
| Magnesium (Mg²⁺) | ↓ Hypomagnesemia | Increases risk | Magnesium is a cofactor for Na⁺/K⁺-ATPase activity and also for maintaining cellular potassium. Low magnesium impairs the pump and often coexists with hypokalemia (loop diuretics deplete both). Hypomagnesemia increases myocardial excitability independently | Check and correct magnesium when managing potassium in patients on digoxin. See electrolyte imbalances reference |
| Calcium (Ca²⁺) | ↑ Hypercalcemia | Increases risk | Digoxin toxicity is driven by excess intracellular calcium. Additional extracellular calcium worsens the intracellular overload and increases the risk of triggered arrhythmias | Avoid rapid IV calcium administration in patients with suspected digoxin toxicity (though calcium may still be needed for hyperkalemia — a clinical judgment call with emergency physician guidance) |
| Calcium (Ca²⁺) | ↓ Hypocalcemia | Mildly protective for arrhythmia (but not a clinical target) | Reduced calcium decreases myocardial excitability, slightly counteracting the calcium overload of digoxin toxicity | Not a clinical target; hypocalcemia causes its own arrhythmia risk (QT prolongation). Monitor as part of overall electrolyte assessment |
Clinical takeaway
The most dangerous electrolyte scenario is a patient on both digoxin and a loop diuretic (furosemide, bumetanide, torsemide). Loop diuretics deplete potassium and magnesium — both of which potentiate digoxin toxicity. This combination requires regular electrolyte monitoring and often co-prescription of potassium supplements.
Antidote: Digibind and DigiFab
When digoxin toxicity is severe, the antidote is digoxin immune Fab (brand names: Digibind, DigiFab). This is one of the few drug-specific antidotes in emergency medicine.
How it works
Digoxin immune Fab consists of antibody fragments (the Fab portion of immunoglobulin G) derived from sheep immunized with digoxin. These fragments bind free digoxin in the serum with very high affinity — higher than digoxin’s binding affinity for Na⁺/K⁺-ATPase. The digoxin-Fab complex is pharmacologically inactive and is cleared by the kidneys.
The result: serum digoxin is rapidly neutralized, the pump inhibition reverses, and the toxic effects diminish. Effects are seen within 30–60 minutes of IV administration.
When to use it
- Life-threatening arrhythmias — ventricular fibrillation, ventricular tachycardia, complete heart block with hemodynamic instability
- Severe bradycardia not responding to atropine
- Hyperkalemia ≥5.0–5.5 mEq/L in the setting of acute digoxin toxicity (indicates massive pump inhibition)
- Ingestion of ≥10 mg in adults (any ingestion in a child)
- Serum digoxin level ≥10–15 ng/mL in acute overdose
- Clinical deterioration despite supportive care
Digibind is NOT indicated for mild toxicity or stable patients who can be managed with dose reduction, electrolyte correction, and monitoring.
Dosing basis
Dosing is based on the estimated body digoxin load, calculated from the serum level and body weight. The formula — (serum level in ng/mL × weight in kg × 5.6) / 1000 = total body load in mg — gives the dose in vials needed. In practice, this calculation is done by the emergency team or pharmacist; the nursing role is to prepare, administer, and monitor response. If the amount ingested is unknown and the patient is deteriorating, an empiric dose (10–20 vials) may be given.
Nursing considerations after Digibind
- Serum digoxin levels become unreliable after Digibind administration — assays measure total digoxin (free + Fab-bound), producing very high and misleading readings. Do not use post-treatment digoxin levels to make clinical decisions.
- Monitor serum potassium closely. Digibind reverses the pump inhibition that was blocking K⁺ cellular uptake. As the pump recovers, K⁺ moves back into cells — serum K⁺ can fall sharply, causing hypokalemia. Replace potassium as needed.
- Monitor for return of HF or AF symptoms — the therapeutic effect of digoxin is also reversed. Patients with HF may need additional support.
- Renal impairment slows clearance of the Fab-digoxin complex and may cause delayed toxicity recurrence (“rebound toxicity”) as Fab is excreted before it can be cleared.
Drug interactions
Digoxin has numerous clinically significant drug interactions. Most either raise serum digoxin levels (increasing toxicity risk) or deplete potassium (which potentiates toxicity at any digoxin level).
| Drug / drug class | Effect on digoxin | Mechanism | Nursing action |
|---|---|---|---|
| Amiodarone | Increases digoxin level by 50–100% | Inhibits P-glycoprotein (renal tubular digoxin secretion) and reduces renal clearance; also inhibits tissue uptake | Reduce digoxin dose by 50% when starting amiodarone; monitor levels closely; expect to adjust further |
| Quinidine | Doubles digoxin level | Inhibits P-glycoprotein; displaces digoxin from tissue binding sites; reduces renal clearance | Reduce digoxin dose by 50% when adding quinidine; monitor for toxicity signs; check levels frequently |
| Verapamil | Increases digoxin level 50–75% | Inhibits P-glycoprotein; reduces renal and non-renal clearance | Reduce digoxin dose; monitor levels; additive AV nodal suppression increases bradycardia risk — monitor HR and PR interval |
| Diltiazem | Increases digoxin level ~20–25% | Inhibits P-glycoprotein; reduces clearance (less effect than verapamil) | Monitor levels and HR; additive bradycardia risk with concurrent AV nodal slowing |
| Loop diuretics (furosemide, bumetanide, torsemide) |
Does NOT directly raise digoxin level — but causes hypokalemia and hypomagnesemia, potentiating toxicity | Urinary K⁺ and Mg²⁺ wasting → competition at Na⁺/K⁺-ATPase binding site reduced → digoxin more potent per level | Monitor K⁺ and Mg²⁺ at least weekly (more often if unstable); supplement K⁺ and Mg²⁺ as needed; educate patient on potassium-rich foods and compliance with supplements |
| Spironolactone / eplerenone | Mild increase in digoxin level; also protective by reducing hypokalemia | Inhibits renal tubular secretion; potassium-sparing effect prevents hypokalemia | Monitor levels; note that spironolactone assay cross-reactivity can spuriously elevate some digoxin assay results — confirm with lab if unexpected |
| Antibiotics (erythromycin, clarithromycin, tetracyclines) |
Can increase digoxin levels significantly | Gut bacteria (Eggerthella lenta) inactivate digoxin in some patients; antibiotics that kill these bacteria remove this inactivation, sharply increasing absorption | Monitor for toxicity when starting antibiotics in digoxin patients; may need level check 1–2 weeks into antibiotic course |
| NSAIDs | Indirect increase via renal impairment | NSAIDs reduce prostaglandin-mediated renal blood flow → reduce GFR → reduce digoxin clearance | Avoid NSAIDs when possible in patients on digoxin; if unavoidable, monitor renal function and digoxin levels more frequently |
| Cholestyramine / antacids | Decrease digoxin absorption | Bind digoxin in the gut; reduce bioavailability | Give digoxin at least 2 hours before cholestyramine or antacids to avoid binding |
Nursing monitoring responsibilities
Safe digoxin administration requires a structured monitoring framework. The following covers the key nursing responsibilities from pre-administration checks through ongoing surveillance for toxicity.
Pre-administration
1. Apical pulse check — the cardinal step
Always assess the apical pulse for a full 60 seconds before giving digoxin. Use a stethoscope over the cardiac apex (5th intercostal space, midclavicular line). Do not use a peripheral pulse — it may miss irregular beats.
Hold the dose and notify the provider if:
- Apical pulse is <60 bpm in adults (general rule)
- Apical pulse is <50 bpm in adults with chronic atrial fibrillation (some sources use this threshold for patients where the goal is rate control rather than rhythm control, as a HR of 50–60 bpm may be their target — follow the individual provider order and know the rationale)
- Pulse is significantly irregular in a new or changing pattern
- Pulse is >100–110 bpm in a patient expected to be rate-controlled — may indicate inadequate dosing or a new clinical problem
Document the apical pulse before every dose. Do not delegate this assessment to someone else before administering the medication.
2. Review recent electrolytes
- Check K⁺ — hold or proceed cautiously if hypokalemic; the threshold for concern is generally K⁺ <3.5 mEq/L but assess the trend
- Check Mg²⁺ and Ca²⁺ when available
- Notify provider if electrolytes are abnormal before giving the dose
3. Review recent digoxin level (if available)
- Is the level therapeutic? When was it drawn? Was the draw timing appropriate (6–8 hours post-dose)?
- If a new level was recently drawn, wait for results before administering a dose in a patient with any symptoms
Ongoing monitoring
| Parameter | Frequency | What to do with abnormal findings |
|---|---|---|
| Apical pulse | Before every dose; telemetry continuously in hospitalized patients | HR <60 (or <50 in AF): hold, document, notify provider. New arrhythmia: hold dose, 12-lead EKG, notify provider urgently |
| Serum potassium | On admission; with each digoxin level check; when starting/adjusting diuretics; any time patient is ill; at minimum every 1–4 weeks in stable outpatients on diuretics | K⁺ <3.5: notify provider for replacement order before giving digoxin; K⁺ <3.0: hold digoxin, urgent replacement |
| Serum magnesium | With potassium monitoring; more frequently in patients on loop diuretics | Mg²⁺ <1.5–1.8: notify provider for replacement; hypomagnesemia impairs potassium repletion — correct Mg²⁺ first |
| Serum digoxin level | After initiating therapy (at steady state: ~7–14 days); after dose changes; every 6–12 months in stable outpatients; any time toxicity is suspected; after any acute illness or significant change in renal function | Level >2.0 ng/mL: hold dose, notify provider, assess for toxicity signs; Level >2.0 with symptoms: prepare for Digibind administration per provider orders |
| Renal function (BUN/Cr) | With each digoxin level; any acute illness; admission; after procedures (contrast, surgery) | Rising creatinine: expect digoxin to accumulate; notify provider to review dose; increase monitoring frequency |
| Daily weight | Every morning, same scale, before eating, after urinating | Gain >2 lb in 24 h or >5 lb in 1 week: may signal worsening HF — report to provider |
| Signs/symptoms of toxicity | Every assessment; specifically inquire about GI symptoms, visual changes, and mood/confusion | Any toxicity symptoms: hold digoxin, check electrolytes and digoxin level, notify provider |
| Fluid status (I&O) | Each shift in hospitalized patients | Decreasing urine output may signal worsening HF or AKI — both affect digoxin clearance and require prompt reporting |
Cardiac rhythm monitoring
For hospitalized patients or during initiation of therapy, continuous telemetry is standard. The nurse should be able to recognize:
- Prolonged PR interval — an early sign of digoxin effect; a PR >0.20 seconds is 1st-degree AV block; progressive PR lengthening warrants evaluation
- Second-degree AV block (Mobitz I / Wenckebach with progressive PR lengthening) — common with digoxin toxicity; hold dose, notify provider
- Third-degree (complete) AV block — medical emergency; often presents as “regularized AF” in patients with AF; hold all AV nodal medications, prepare for Digibind
- PVCs in bigeminy (every other beat is a PVC) — classic but non-specific pattern with digoxin toxicity; evaluate in clinical context
- Bidirectional ventricular tachycardia — alternating QRS axis on ECG; highly specific for digoxin toxicity and a life-threatening arrhythmia
For a full clinical breakdown of first-degree, Wenckebach, Mobitz II, and complete heart block — including the nursing mnemonic used to distinguish them — see the heart block poem. Refer to the cardiac arrhythmias nursing guide for broader rhythm interpretation detail.
Patient education
Effective patient teaching is one of the most important nursing contributions to digoxin safety. Most chronic digoxin toxicity occurs in outpatients — and most of it is preventable with good education.
Key teaching points
How to take digoxin correctly:
- Take at the same time every day. Consistent timing helps maintain steady serum levels.
- Take with or without food, but avoid taking with high-fiber meals, which may reduce absorption slightly.
- Do not double up if a dose is missed. Missed dose rule: if you remember within 12 hours of your scheduled time, take it. If it is closer to your next dose time, skip the missed dose and take the next one as scheduled. Never take two doses at once.
- Store at room temperature, away from moisture. Do not store in the bathroom.
- Do not crush tablets without checking — digoxin tablets are typically scored for splitting, and some formulations should not be altered.
How to check your pulse: Teach every patient on digoxin to check their own pulse. The standard teaching is the radial pulse technique:
- Use the pads of the index and middle fingers on the inside of the wrist, below the thumb
- Count for 60 full seconds (not 15 seconds × 4 — irregular rhythms need a full minute)
- If pulse is below 60 bpm (or the threshold specified by their provider), do not take the digoxin that day; call the clinic or provider before the next dose
For patients with AF who may always have an irregular pulse, clarify with the provider what their specific hold threshold is — it may differ from the standard 60 bpm.
What symptoms to report immediately:
- Nausea, vomiting, or loss of appetite that is new or worsening
- Seeing yellow or green tints or halos around lights
- Blurred vision
- New or worsening confusion, unusual tiredness, or weakness
- Palpitations, unusually slow or fast heartbeat
- Weight gain of more than 2 lb in a day or 5 lb in a week (signals worsening HF)
Medications and supplements to discuss with the provider:
- Any new prescription medications (especially antibiotics, heart medications, antifungals)
- Over-the-counter medications including antacids, NSAIDs (ibuprofen, naproxen), and herbal products
- St. John’s Wort (herbal antidepressant) — induces P-glycoprotein and CYP enzymes, reducing digoxin levels and effect
Potassium intake: Patients on digoxin plus loop diuretics should be counseled on potassium-rich foods (bananas, oranges, potatoes, tomatoes, leafy greens) and should not make dramatic changes in potassium intake without consulting their provider. If prescribed a potassium supplement, take it consistently. Do not take extra potassium without guidance — too much potassium (especially with ACE inhibitors or potassium-sparing diuretics) can cause dangerous hyperkalemia.
Lab tests and appointments:
- Stress the importance of regular lab monitoring (electrolytes, digoxin level, renal function)
- If told to come in for blood work before taking the morning dose, follow that instruction — the timing of the draw relative to the dose matters for accurate interpretation
- Do not miss follow-up appointments
Dietary consistency: Major changes in fluid and electrolyte intake affect digoxin behavior. Advise patients to maintain consistent dietary patterns and report significant dietary changes (crash diets, illness with vomiting/diarrhea) to their provider.
Nursing diagnoses
The following nursing diagnoses are relevant for patients receiving digoxin therapy. Priority depends on individual patient assessment.
1. Decreased cardiac output related to altered heart rate, rhythm, or contractility as evidenced by fatigue, dyspnea, reduced activity tolerance, and hemodynamic changes.
Interventions: Apical pulse before each dose; continuous cardiac monitoring; daily weight; I&O monitoring; assess for signs of worsening HF or therapeutic response; coordinate medication timing; educate patient on self-monitoring.
2. Risk for poisoning related to narrow therapeutic index, polypharmacy interactions, and renal function changes.
Interventions: Verify digoxin level and electrolytes before administration; assess for toxicity signs each shift; review interacting medications; monitor renal function; maintain accurate medication administration record; patient education on toxicity symptoms.
3. Deficient knowledge related to new medication regimen, monitoring requirements, and toxicity recognition.
Interventions: Teach pulse-taking technique; review missed dose instructions; explain toxicity signs to report; provide written materials; verify comprehension with teach-back; include family members in teaching.
4. Risk for electrolyte imbalance (hypokalemia) related to concurrent loop diuretic use.
Interventions: Monitor K⁺ per schedule; assess for hypokalemia symptoms (muscle weakness, cramps, EKG changes); administer potassium supplements as ordered; educate on dietary sources; contact provider for K⁺ <3.5 mEq/L; review combined medication list for additive depletion risk.
5. Ineffective health maintenance related to complex medication regimen, multiple comorbidities, and need for ongoing monitoring.
Interventions: Simplify medication schedule where possible; identify barriers to adherence; set up medication reminder systems; ensure follow-up laboratory appointments are scheduled before discharge; coordinate with pharmacy for blister packaging if needed.
NCLEX tips
| # | Tip |
|---|---|
| 1 | Always check apical pulse for 60 seconds before giving digoxin. Hold and notify the provider if the rate is <60 bpm in adults. This is the most frequently tested nursing action for digoxin. |
| 2 | Hypokalemia is the most dangerous electrolyte disturbance with digoxin. Low K⁺ increases digoxin binding to Na⁺/K⁺-ATPase → more toxicity at the same serum level. Know this mechanism. |
| 3 | GI symptoms (nausea, vomiting, anorexia) are often the FIRST sign of digoxin toxicity — before cardiac arrhythmias develop. Any patient on digoxin with new nausea warrants level + electrolyte check. |
| 4 | Yellow-green halos around lights (xanthopsia) = classic visual sign of digoxin toxicity. It will appear on NCLEX. Recognize it, hold the dose, check the level. |
| 5 | "Regularized AF" = complete AV block from digoxin toxicity. If a patient with known AF develops a regular rhythm, this is not a good sign — it is a medical emergency. |
| 6 | Draw digoxin levels 6–8 hours after the last dose. Levels drawn earlier reflect distribution, not tissue equilibration — they are falsely elevated and will lead to wrong clinical decisions. |
| 7 | The current therapeutic target for HF is 0.5–0.9 ng/mL — NOT the historical 1.5–2.0 ng/mL. The DIG trial showed higher levels do not improve outcomes and may increase mortality. |
| 8 | Digoxin does NOT reduce mortality in HF. It reduces hospitalizations. This is a classic NCLEX distractor — know the difference between reducing hospitalizations and improving survival. |
| 9 | The antidote to digoxin toxicity is Digibind (digoxin immune Fab). After giving Digibind, serum digoxin levels will be unreliable — the assay detects total (bound + unbound) digoxin and reads very high. Do not use post-Digibind levels for clinical decisions. |
| 10 | Digoxin is renally cleared. Any decrease in renal function (AKI, dehydration, NSAIDs, contrast) raises digoxin levels. This is a high-frequency scenario on NCLEX boards. |
| 11 | Amiodarone doubles digoxin levels. When a patient on digoxin is started on amiodarone, the digoxin dose must be reduced by 50% and levels monitored closely. |
| 12 | Loop diuretics + digoxin = hypokalemia risk. The diuretic depletes K⁺; low K⁺ potentiates digoxin. Patients on both need regular K⁺ monitoring and often K⁺ supplementation. |
| 13 | Hypomagnesemia also potentiates digoxin toxicity — same general mechanism (cofactor for Na⁺/K⁺-ATPase). Correct Mg²⁺ first when repleting K⁺, because you cannot correct hypokalemia effectively in the setting of low magnesium. |
| 14 | Hypercalcemia worsens digoxin toxicity. Digoxin works by raising intracellular calcium — adding more extracellular calcium compounds the effect. This is why rapid IV calcium is used cautiously in patients with possible digoxin toxicity. |
| 15 | Digoxin is NOT first-line for HF or AF. It is an add-on after more effective agents (beta-blockers, ACE inhibitors/ARBs, aldosterone antagonists) are optimized. Questions about first-line treatment should not select digoxin. |
| 16 | Bidirectional ventricular tachycardia on EKG = digoxin toxicity until proven otherwise. This pattern (alternating QRS axis) is highly specific for cardiac glycoside toxicity. |
| 17 | Patient teaching: take the pulse before each dose at home. If below 60, skip the dose and call the provider. Never take a double dose. |
| 18 | Long half-life (~36–48 hours) means toxicity takes days to resolve without antidote. Supportive care — holding the drug, correcting electrolytes, monitoring cardiac rhythm — is required for days after stopping the medication. |
| 19 | Quinidine doubles digoxin levels via P-glycoprotein inhibition and displacement from tissue-binding sites. Reduce digoxin by 50% when adding quinidine; monitor frequently. |
| 20 | St. John's Wort reduces digoxin levels (P-glycoprotein induction → more digoxin excreted in gut/tubule). Patients taking herbal supplements need to disclose them — loss of efficacy in AF rate control or HF management can occur without obvious cause. |
NCLEX scenarios
| # | Scenario | Answer and rationale |
|---|---|---|
| 1 | A patient with heart failure is scheduled for their 0900 digoxin dose. The nurse assesses an apical pulse of 54 bpm. What is the priority nursing action? | Hold the digoxin dose, document the finding, and notify the provider. The hold parameter for digoxin is a pulse <60 bpm in adults. Administering the dose would increase the risk of further bradycardia and cardiac arrhythmia. |
| 2 | A patient on digoxin 0.125 mg/day reports nausea and loss of appetite over the past two days. Serum K⁺ is 2.9 mEq/L. What does the nurse recognize? | Signs consistent with digoxin toxicity potentiated by hypokalemia. GI symptoms (nausea, anorexia) are the earliest signs of toxicity. K⁺ of 2.9 mEq/L is significantly low and increases digoxin binding to Na⁺/K⁺-ATPase. Hold the dose, notify the provider, and anticipate orders for a digoxin level and K⁺ replacement. |
| 3 | A patient with atrial fibrillation on digoxin is noted to have a regular pulse of 46 bpm on the monitor. Their rhythm had been consistently irregular on prior assessments. What does this finding indicate? | Possible complete AV block (third-degree heart block) from digoxin toxicity. "Regularized AF" — a regular rhythm in a patient with known AF — is a hallmark of digitalis toxicity. The regular escape rhythm suggests complete AV block. This is a medical emergency: hold the medication, perform a 12-lead EKG, notify the provider immediately, and prepare for potential Digibind administration. |
| 4 | A patient on digoxin is started on amiodarone for a new arrhythmia. What does the nurse anticipate? | The digoxin dose will need to be reduced by approximately 50%. Amiodarone inhibits P-glycoprotein, reducing renal tubular secretion of digoxin, and can double serum digoxin levels. Failure to reduce the dose will likely result in toxicity. Anticipate a provider order to halve the digoxin dose and increase monitoring frequency. |
| 5 | The nurse is reviewing a digoxin level of 2.6 ng/mL. The blood was drawn 2 hours after the morning dose. How should the nurse interpret this result? | The result is unreliable — timing is incorrect. Levels drawn within 6 hours of a dose reflect the distribution phase, not the equilibrated serum concentration. The elevated result likely represents the distribution phase, not true toxicity. The nurse should hold the dose, notify the provider, and arrange for a repeat level drawn 6–8 hours after the next dose. Do not assume toxicity based on a mis-timed level — but also do not give the dose without provider guidance. |
| 6 | A patient reports seeing yellow-green halos around the hospital room lights. They are receiving digoxin 0.25 mg/day. What is the nurse's priority action? | Hold the digoxin, check vital signs including apical pulse, notify the provider, and anticipate orders for a digoxin level and electrolytes. Yellow-green halos (xanthopsia) are a classic neurological/visual sign of digoxin toxicity. This symptom should never be dismissed in a patient on digoxin. |
| 7 | A nurse is providing discharge teaching to a patient newly started on digoxin. Which patient statement indicates a need for further teaching? | "If I miss my morning dose, I'll take two pills that evening to catch up." — This statement requires correction. Doubling a dose to compensate for a missed dose is dangerous with digoxin. The correct instruction is: if you remember within 12 hours of your scheduled dose time, take it; if closer to the next dose time, skip the missed dose and resume the normal schedule. |
| 8 | A patient with HFrEF asks why they are prescribed digoxin. Which explanation by the nurse is most accurate? | "Digoxin helps your heart pump more effectively and will likely reduce your chances of being hospitalized for heart failure, but it has not been shown to extend your life." This accurately reflects the DIG trial findings. Digoxin improves symptoms and reduces HF hospitalizations but does not reduce mortality. Nurses should not claim a mortality benefit. |
| 9 | Which electrolyte finding requires the nurse to hold digoxin and notify the provider before administration? | Serum K⁺ of 2.8 mEq/L. Hypokalemia (K⁺ below approximately 3.0–3.5 mEq/L) significantly potentiates digoxin toxicity by reducing competition at the Na⁺/K⁺-ATPase binding site. Administering digoxin to a hypokalemic patient risks serious toxicity even at standard doses. |
| 10 | A patient in the ED has taken an estimated 15 mg of digoxin in a suicide attempt. Serum K⁺ is 6.2 mEq/L and EKG shows complete heart block. What is the priority intervention? | Administer digoxin immune Fab (Digibind) as ordered. Acute ingestion of ≥10 mg, life-threatening arrhythmia (complete heart block), and hyperkalemia (≥5.0–5.5 mEq/L from massive Na⁺/K⁺-ATPase inhibition blocking cellular K⁺ uptake) are all indications for Digibind. Supportive care alone is insufficient in this presentation. |
| 11 | After Digibind administration, a digoxin level returns at 18 ng/mL. How should the nurse interpret this? | The level is uninterpretable and should not be used for clinical decisions. After Digibind administration, the assay measures total digoxin — free drug plus Fab-bound complexes. The bound digoxin is pharmacologically inert, but the assay cannot distinguish it. Post-Digibind serum digoxin levels appear very high and are meaningless for treatment decisions. Assess clinical response instead. |
| 12 | A patient on digoxin and furosemide has been vomiting for 24 hours from gastroenteritis. Which complication is the nurse most concerned about? | Digoxin toxicity potentiated by electrolyte depletion. Vomiting causes K⁺ and Mg²⁺ losses; furosemide also depletes both electrolytes. The combined depletion can precipitate digoxin toxicity even without any change in the digoxin dose. Check electrolytes and digoxin level urgently. Assess for GI, cardiac, and neurological toxicity signs. |
| 13 | A patient asks whether they can take ibuprofen for back pain while on digoxin. What is the best nursing response? | Advise against it and instruct the patient to consult their provider. NSAIDs reduce renal prostaglandin production, decreasing GFR and slowing digoxin clearance. This can raise serum digoxin levels into the toxic range. Acetaminophen is a safer alternative for most patients. |
| 14 | The nurse is monitoring a patient on digoxin. Which EKG change is most specific for digoxin toxicity? | Bidirectional ventricular tachycardia (alternating QRS axis, positive and negative alternating). This pattern is highly specific for cardiac glycoside toxicity and is a medical emergency requiring immediate intervention, including Digibind. |
| 15 | A patient with CKD Stage 4 (eGFR 22 mL/min) is admitted with digoxin toxicity. Their digoxin level is 2.8 ng/mL. What is the primary pharmacokinetic explanation? | Reduced renal clearance of digoxin. Digoxin is 60–80% renally excreted unchanged. With an eGFR of 22, elimination is markedly impaired — digoxin accumulates to toxic levels even on doses that would be safe with normal renal function. In CKD, doses must be substantially reduced and monitoring intensified. |
| 16 | Which of the following actions should the nurse take when teaching a patient to self-monitor their pulse at home on digoxin? | Instruct the patient to count the pulse for a full 60 seconds. Counting for 15 seconds and multiplying by 4 is insufficient in patients with irregular rhythms (as in AF). A full 60 seconds provides an accurate rate and allows detection of irregularity. The patient should also know the threshold below which they should hold the dose and call the provider. |
| 17 | A nurse is caring for a patient on digoxin who is also taking spironolactone. What benefit does spironolactone provide in this combination? | Spironolactone is potassium-sparing, helping maintain K⁺ levels and reducing the risk of hypokalemia-mediated digoxin toxicity. It also has mortality-reducing benefits in HFrEF independently. Unlike loop diuretics, it does not deplete potassium — it actually raises serum potassium by blocking aldosterone-driven K⁺ excretion. |
| 18 | A patient on digoxin reports taking a St. John's Wort supplement for depression. The nurse's concern is: | St. John's Wort induces P-glycoprotein and CYP enzymes, reducing digoxin absorption and increasing tubular secretion — it lowers serum digoxin levels. Patients may lose therapeutic effect without understanding why. The nurse should instruct the patient to inform their provider and avoid adding, stopping, or changing herbal supplements without guidance, as these changes can shift digoxin levels unpredictably. |
| 19 | Which of the following is a contraindication to giving digoxin? | Ventricular fibrillation or ventricular tachycardia (absent other indication). Also: WPW syndrome with AF (digoxin can accelerate conduction down the accessory pathway, potentially precipitating VF). Second- or third-degree AV block without a functioning pacemaker is a strong contraindication — adding AV nodal suppression to an already blocked node is dangerous. |
| 20 | A patient on digoxin and a loop diuretic has a serum K⁺ of 3.2 mEq/L. The provider orders potassium chloride 40 mEq IV over 4 hours. What monitoring does the nurse prioritize during infusion? | Continuous cardiac monitoring and IV site assessment throughout infusion. Potassium is a vesicant and can cause cardiac arrhythmias if infused too rapidly. The maximum peripheral IV rate is generally 10 mEq/hour; 40 mEq over 4 hours (10 mEq/hr) is at the upper limit for peripheral infusion. The nurse should monitor the EKG for peaked T waves or widening QRS (signs of hyperkalemia overshoot), assess the IV site for infiltration, and recheck K⁺ after completion. |
Summary
Digoxin occupies a unique position in nursing pharmacology: it is old, narrow, and unforgiving — but its mechanism, toxicity pattern, and monitoring requirements all follow a coherent logic that makes it learnable and manageable. The Na⁺/K⁺-ATPase mechanism explains both the drug’s therapeutic effect and its toxicity. The three toxicity categories — GI first, then cardiac and neurological — follow from that mechanism. The electrolyte interactions (hypokalemia as the major amplifier) make biochemical sense once the mechanism is understood.
For nurses, the clinical imperatives are clear: check the apical pulse before every dose, monitor electrolytes routinely and urgently when anything changes, recognize the early warning signs of GI toxicity before cardiac arrhythmias develop, and teach patients to participate in their own safety monitoring. When toxicity occurs, Digibind provides an effective reversal — but post-treatment vigilance for hypokalemia and rebound is required.
For NCLEX, digoxin is one of the most frequently tested medications — for good reason. The questions reward nurses who understand not just the rules but the reasons behind them.
For further depth, explore the cardiovascular medications nursing guide for this drug in context with other cardiac pharmacology, and the electrolyte imbalances reference for comprehensive electrolyte management principles.